Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance with a notable increase in revenue and net profit, indicating strong growth potential in the orthopedic medical device sector [2][3] - As of September 30, 2025, Spring Medical achieved an operating income of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [2] - The company has a high financing balance of 40.56 million yuan, which accounts for 0.57% of its market capitalization, indicating a strong position in the market [1] Group 2 - Spring Medical primarily engages in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prostheses and spinal implants [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 13,200 shares on December 1, 2025, marking a cumulative net reduction of 644,200 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Spring Medical on 11 occasions, resulting in a total net reduction of 283,800 shares [1] - As of the latest data, southbound funds hold 43,889,800 shares of Spring Medical, which accounts for 46.12% of the company's total issued ordinary shares [1] Group 2 - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implant products [2] - The company's joint prosthetic products cover four major human joints: hip, knee, shoulder, and elbow, while its spinal implant products consist of a full range of spinal fixation systems [2] - Spring Medical's products are exported to various countries and regions across Asia, South America, Africa, Oceania, and Europe [2]

Group 1 - The stock of Chunli Medical (688236) closed at 24.52 yuan on December 1, 2025, with a slight increase of 0.25% and a turnover rate of 0.51% [1] - The net inflow of main funds on December 1 was 969,700 yuan, accounting for 2.67% of the total transaction amount, while retail investors had a net inflow of 910,300 yuan, representing 2.51% [1] - Over the past five days, the stock has shown fluctuations in fund flows, with notable net inflows and outflows from different investor categories [1] Group 2 - Chunli Medical's total market value is 9.405 billion yuan, which is below the industry average of 11.157 billion yuan, ranking 38 out of 124 in the medical device sector [2] - The company reported a net profit of 192 million yuan for the first three quarters of 2025, reflecting a significant year-on-year increase of 213.21%, with a gross margin of 67.27% [2] - The third quarter of 2025 saw a remarkable 109.51% year-on-year increase in main revenue, reaching 268 million yuan, and a net profit of 77.06 million yuan, up 531.12% year-on-year [2] Group 3 - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set at 31.8 yuan [3]

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, with ongoing development of customized dental implants [2][3] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is located in Tongzhou District, Beijing, specializing in implantable orthopedic medical devices [7][8] - The company's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal fixation systems [8] Financial Performance - For the period from January to September 2025, Spring Medical achieved revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3] - The company is positioned within the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept sectors including dental medical, financing, and robotics [8] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and other new entrants, indicating a diversification in shareholder base [9]

来源：新浪证券-红岸工作室 11月28日，春立医疗涨0.49%，成交额3195.81万元。两融数据显示，当日春立医疗获融资买入额535.08 万元，融资偿还307.67万元，融资净买入227.41万元。截至11月28日，春立医疗融资融券余额合计 4193.37万元。 截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 融资方面，春立医疗当日 ...

格隆汇11月28日丨春立医疗(01858.HK)公告，北京市春立正达医疗器械股份有限公司已于2025年10月31 日发布公司2025年第三季度报告，为便于广大投资者更全面深入地了解公司2025年第三季度经营成果、 财务状况，公司计划于2025年12月8日上午10:00-11:00举行2025年第三季度业绩说明会，就投资者关心 的问题进行交流。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 证券代码：688236 证券简称：春立医疗 公告编号：2025-049 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於召開2025 年第三季度業績說明會的公告》，僅供參閱。 承董事 ...

截至2025年11月28日收盘，春立医疗（688236）报收于24.46元，较前一交易日上涨0.49%，最新总市值 为93.82亿元。该股当日开盘24.56元，最高24.56元，最低23.94元，成交额达3195.81万元，换手率为 0.46%。 公司近日发布公告称，北京市春立正达医疗器械股份有限公司将于2025年12月8日上午10:00-11:00通过 上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务 状况。参会人员包括董事长史文玲、总经理史春生、财务总监卢宏悦及董事会秘书解凤宝。投资者可于 2025年12月1日至12月5日16:00前通过上证路演中心或公司邮箱ir@clzd.com提交问题。说明会结束后可 通过上证路演中心查看会议情况。 《关于召开2025年第三季度业绩说明会的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 ...

| 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 93.82亿元 | 111.44亿元 | 38 124 | | 净资产 | 29.86亿元 | 38.93亿元 | 51 124 | | 净利润 | 1.92亿元 | 2.12亿元 | 33 124 | | 市盈率(动) | 36.74 | 57.71 | 41 124 | | 市净率 | 3.14 | 3.89 | 76 124 | | 毛利率 | 67.27% | 51.22% | 27 124 | | 净利率 | 25.34% | 9.57% | 22 124 | | ROE | 6.6% | 0.15% | 33 124 | 11月28日的资金流向数据方面，主力资金净流入290.07万元，占总成交额9.08%，游资资金净流出 229.62万元，占总成交额7.18%，散户资金净流出60.45万元，占总成交额1.89%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | - ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-049 北京市春立正达医疗器械股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 12 月 1 日（星期一）至 12 月 5 日（星期五）16:00 前登录上证 路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三 季度经营成果、财务状况，公司计划于 2025 年 12 月 8 日上午 10:00-11:00 举行 2025 年第 三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经营成果及 财务指标的具体情况与投 ...